Octapharma's wilate wins FDA nod for VWD prophylaxis in kids under 6
The expanded approval rests on a 12-patient Phase 3 trial showing an annualized bleeding rate of 4.6, with no thrombotic events, in the first VWF concentrate cleared for prophylaxis across all VWD ages.
Executive Summary
- Octapharma's wilate secured FDA clearance to extend prophylactic use in von Willebrand Disease down to children under 6, closing the last age gap in the drug's label.
- A small pediatric trial produced a bleeding rate consistent with wilate's established performance in older patients, with a favorable safety readout and no comparator arm to benchmark it against.
- Because wilate was already approved for prophylaxis in adults and older children, the relevant test was replication in a younger population, not a new efficacy threshold.
- Wilate now stands as the only Phase 3 asset targeting Factor VIII specifically within von Willebrand Disease, in a field where most Factor VIII programs are built around hemophilia rather than this indication.
The approval
The FDA approved wilate (von Willebrand Factor/Coagulation Factor VIII Complex) on July 2, 2026, for routine prophylaxis to reduce bleeding frequency in pediatric patients with von Willebrand Disease younger than 6 years old, Octapharma USA said in a press release. The expansion means wilate now covers prophylactic treatment across all ages and severity types of the disease, the most common inherited bleeding disorder. "Until now, pediatric hematologists have not had an FDA-approved option for routine prophylaxis in young children with VWD," said Flemming Nielsen, President of Octapharma USA. OctapharmaOctapharma USA Announces Expanded FDA Approval of wilate® for von Willebrand Disease Prophylaxis in Children Younger Than 6 YearsJul 8, 2026
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
The trial
The label rests on the Phase 3 WIL-33 trial (NCT04953884), an open-label study that enrolled 12 patients under age 6 with severe von Willebrand Disease and administered wilate two to three times weekly at 30 to 50 IU/kg over 12 months. The trial's primary endpoint was total annualized bleeding rate during prophylaxis. Over that period, the annualized bleeding rate measured 4.6, with a standard deviation of 6.1. Of 56 bleeding episodes recorded, 98.2% were classified as minor, and of the 45 bleeds actually treated, 95.6% resolved with a single infusion. No thrombotic events or Factor VIII accumulation were observed over the 12-month course. NCT04953884+1Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of AgeNCT04953884Octapharma USA Announces Expanded FDA Approval of wilate® for von Willebrand Disease Prophylaxis in Children Younger Than 6 YearsJul 8, 2026
What the trial had to show
Wilate was already established as a prophylaxis option in adults and children 6 and older through the earlier WIL-31 study, the largest prospective study of wilate prophylaxis in that older group. Octapharma said WIL-33 showed a similar prophylactic effect in the younger cohort to what WIL-31 demonstrated in older patients. Because the drug's efficacy was already established outside this age band, the trial's job was to reproduce that result in children under 6, not to clear a new efficacy bar. The absence of a comparator arm and the 12-patient size mean the readout functions as a bridging confirmation for the label rather than a standalone efficacy proof. OctapharmaOctapharma USA Announces Expanded FDA Approval of wilate® for von Willebrand Disease Prophylaxis in Children Younger Than 6 YearsJul 8, 2026
The trial's path to completion
The study's primary completion date moved seven times between its 2021 registration and its actual close, sliding from an original target of December 2022 out to December 2024 before the trial completed on schedule against its final guidance. Enrollment held flat at its target of 12 patients throughout, with no growth or shortfall against the original design. The trial finished, and results posted to the registry on February 20, 2026, roughly five months before the press release disclosing the data and the resulting approval. NCT04953884+1Efficacy, PK, Immunogenicity and Safety of Wilate in Severe Von Willebrand Disease (VWD) Patients <6 Years of AgeNCT04953884Octapharma USA Announces Expanded FDA Approval of wilate® for von Willebrand Disease Prophylaxis in Children Younger Than 6 YearsJul 8, 2026
Where wilate sits
Within Factor VIII programs specifically registered against von Willebrand Disease, wilate is the only asset that has reached Phase 3. The broader von Willebrand Disease field includes Takeda's Vonicog Alfa, also a Factor VIII/VWF replacement therapy now enrolling a Phase 3 pediatric study, and earlier-stage non-replacement candidates such as Vega Therapeutics' VGA039. Most other Factor VIII-targeted programs in active development sit in hemophilia A rather than von Willebrand Disease, a distinction that leaves wilate's specific pediatric prophylaxis niche without a direct Phase 3 rival at this age band. NCT07129343
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.